Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Cardio-Oncology · Anthracycline-Induced Cardiomyopathy

Calculating and Managing Your Heart Risk

At a Glance

Anthracycline heart risk is estimated from existing heart conditions, age, cumulative chemotherapy dose, chest radiation, and other drugs. The result guides how closely your heart is monitored and whether protective treatment or chemotherapy changes should be discussed with your care team.

Before you begin anthracycline treatment, your medical team performs a “safety check” for your heart. This process, called baseline risk stratification, helps doctors predict how your heart might respond to chemotherapy so they can tailor your monitoring and protection plan [1][2].

The HFA-ICOS Scoring System

Specialists often use a standardized tool developed by the Heart Failure Association (HFA) and the International Cardio-Oncology Society (ICOS) to estimate your risk [1]. This tool looks at your health history and your specific cancer treatment plan to place you into one of four categories [3]:

  • Low Risk: Monitoring is standard. However, low risk is not zero risk, and heart changes can still occur [4].
  • Medium Risk: Requires slightly more frequent check-ups during treatment [4].
  • High Risk: Your team may involve a cardio-oncologist (a heart specialist for cancer patients) and carefully consider if protective medications are right for you [4][5].
  • Very High Risk: Intensive heart monitoring is required, and your oncology team may discuss modifying the chemotherapy plan to protect your heart [4][5].

It is important to remember that this score is a clinical estimation tool, not a guarantee of what will happen. It helps your team make decisions, but does not replace their personalized clinical judgment.

Factors That Shape Your Risk

Your score is a combination of “patient factors” and “treatment factors” [1][6].

Patient-Specific Factors

  • Existing Heart Conditions: Prior heart failure, heart attack, or an abnormal baseline heart scan significantly increase risk [1][7].
  • Traditional Health Markers: High blood pressure (hypertension), diabetes, obesity, smoking history, and high cholesterol all play a role [6][8].
  • Age: Risk is generally higher for very young children (whose hearts are still developing) and older adults [6][8].

Treatment-Specific Factors

  • Cumulative Dose: The risk of damage is directly continuous with the total amount of anthracycline you receive over your lifetime [9][7]. There is no “perfectly safe” cutoff, but for doxorubicin, passing markers like 250 mg/m² is commonly recognized as an indicator of substantially higher risk [9].
  • Radiation Therapy: If you also receive radiation to the chest or mediastinum (the area between the lungs), the risk to the heart muscle and valves increases [6][10].
  • Combination Therapies: Some other cancer drugs, such as trastuzumab (Herceptin), can add stress to the heart when used alongside or after anthracyclines [3][1].

How Your Team Uses This Information

Your risk category is a roadmap for your care, not a barrier to treatment [2]. Based on your risk, your doctors may take several proactive steps:

  1. More Frequent Monitoring: You may have echocardiograms or blood tests (like troponin) more often than standard intervals [11][12].
  2. Protective Medications: For select high-risk patients, doctors may discuss prescribing ACE inhibitors or beta-blockers to help “shield” the heart muscle, though evidence for primary prevention is mixed and must be weighed against side effects [13][14].
  3. Treatment Adjustments: In very high-risk situations, doctors might use a “liposomal” version of the drug or add a protective drug called dexrazoxane [15][16].

Knowing your risk category allows you to be an active participant in your care [5][17].

Common questions in this guide

What does my HFA-ICOS heart-risk category mean?
The HFA-ICOS score combines your health history with your planned cancer treatment to estimate the chance of anthracycline-related heart problems. Low, medium, high, and very high categories help determine monitoring and prevention, but the score is not a guarantee and does not replace your doctors’ judgment.
Which health and treatment factors raise the risk of anthracycline heart damage?
Risk can be higher with prior heart failure or heart attack, an abnormal baseline heart scan, high blood pressure, diabetes, obesity, smoking history, high cholesterol, or very young or older age. A higher lifetime anthracycline dose, chest radiation, and treatment with trastuzumab can add risk.
How does the total anthracycline dose affect heart risk?
Heart risk increases with the total amount of anthracycline received over a lifetime, and there is no single dose that is perfectly safe for everyone. For doxorubicin, reaching about 250 mg/m² is commonly treated as a marker of substantially higher risk, but your other health and treatment factors also matter.
How will my heart be monitored during anthracycline treatment?
Your monitoring plan may include echocardiograms, which use ultrasound to look at heart function, and blood tests such as troponin. Higher-risk patients may need these checks more often and may be referred to a cardio-oncologist, a heart specialist who works with people receiving cancer treatment.
Can medicines or treatment changes lower my heart risk?
For selected high-risk patients, doctors may discuss ACE inhibitors or beta-blockers, although evidence for preventing heart problems before they start is mixed and side effects must be considered. In very high-risk situations, the team may consider a liposomal form of the anthracycline, dexrazoxane, or changes to the chemotherapy plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my HFA-ICOS score, what is my specific risk category (Low, Medium, High, or Very High)?
  2. 2.How will my risk category change how often you check my heart with echocardiograms or blood tests?
  3. 3.What is the planned total cumulative dose of anthracyclines for my treatment, and does it approach standard higher-risk thresholds?
  4. 4.If I am in a higher risk category, should we consider using a liposomal version of the drug or adding dexrazoxane to protect my heart?
  5. 5.Do my other health conditions, like my blood pressure or blood sugar levels, need to be managed more strictly during my chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

    Lyon AR, Dent S, Stanway S, et al.

    European journal of heart failure 2020; (22(11)):1945-1960 doi:10.1002/ejhf.1920.

    PMID: 32463967
  2. 2

    Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps.

    Tong J, Senechal I, Ramalingam S, Lyon AR

    British journal of hospital medicine (London, England : 2005) 2025; (86(1)):1-21 doi:10.12968/hmed.2024.0632.

    PMID: 39862029
  3. 3

    Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis.

    Gomes C, Geels J, Debray TPA, et al.

    BMJ (Clinical research ed.) 2025; (390()):e084062 doi:10.1136/bmj-2025-084062.

    PMID: 40987514
  4. 4

    Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.

    Rivero-Santana B, Saldaña-García J, Caro-Codón J, et al.

    European heart journal 2025; (46(3)):273-284 doi:10.1093/eurheartj/ehae496.

    PMID: 39106857
  5. 5

    The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.

    Di Lisi D, Madaudo C, Faro DC, et al.

    Journal of cardiovascular medicine (Hagerstown, Md.) 2024; (25(3)):218-224 doi:10.2459/JCM.0000000000001589.

    PMID: 38305134
  6. 6

    Case of Anthracycline-induced Cardiogenic Shock: A Call to Optimize Modifiable Cardiac Risk Factors Prior to Chemotherapy.

    Gabriel A, Stringer B, Hadfield MJ, Madady M

    Cureus 2019; (11(6)):e4961 doi:10.7759/cureus.4961.

    PMID: 31497415
  7. 7

    Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis.

    Jin H, Xu J, Sui Z, Wang L

    Frontiers in cardiovascular medicine 2023; (10()):1101585 doi:10.3389/fcvm.2023.1101585.

    PMID: 36742068
  8. 8

    Heart Failure in Relation to Anthracyclines and Other Chemotherapies.

    Agunbiade TA, Zaghlol RY, Barac A

    Methodist DeBakey cardiovascular journal 2019; (15(4)):243-249 doi:10.14797/mdcj-15-4-243.

    PMID: 31988684
  9. 9

    Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

    Henriksen PA

    Heart (British Cardiac Society) 2018; (104(12)):971-977 doi:10.1136/heartjnl-2017-312103.

    PMID: 29217634
  10. 10

    An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study.

    Yoodee J, Sookprasert A, Sanguanboonyaphong P, et al.

    Clinics and practice 2021; (11(3)):484-493 doi:10.3390/clinpract11030064.

    PMID: 34449564
  11. 11

    Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

    Pudil R, Mueller C, Čelutkienė J, et al.

    European journal of heart failure 2020; (22(11)):1966-1983 doi:10.1002/ejhf.2017.

    PMID: 33006257
  12. 12

    Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy.

    Liu J, Banchs J, Mousavi N, et al.

    JACC. Cardiovascular imaging 2018; (11(8)):1122-1131 doi:10.1016/j.jcmg.2018.03.025.

    PMID: 30092969
  13. 13

    Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial.

    Marwick TH, Dewar E, Nolan M, et al.

    European heart journal 2024; (45(41)):4414-4424 doi:10.1093/eurheartj/ehae574.

    PMID: 39217601
  14. 14

    Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.

    Caspani F, Tralongo AC, Campiotti L, et al.

    Internal and emergency medicine 2021; (16(2)):477-486 doi:10.1007/s11739-020-02508-8.

    PMID: 33011930
  15. 15

    Prevention of chemotherapy-induced left ventricular dysfunction.

    Bisceglia I, Canale ML, Cartoni D, et al.

    European heart journal supplements : journal of the European Society of Cardiology 2021; (23(Suppl E)):E28-E32 doi:10.1093/eurheartj/suab085.

    PMID: 35233212
  16. 16

    Minimizing cardiac toxicity in children with acute myeloid leukemia.

    Narayan HK, Getz KD, Leger KJ

    Hematology. American Society of Hematology. Education Program 2021; (2021(1)):368-375 doi:10.1182/hematology.2021000268.

    PMID: 34889355
  17. 17

    Assessment of Chemotherapy-Induced Cardiac Dysfunction in Breast Cancer Patients: A Prospective Study.

    Singh J, Iqbal SA, Gajula S, et al.

    Cureus 2024; (16(5)):e59461 doi:10.7759/cureus.59461.

    PMID: 38826896

This page explains how clinicians estimate and manage the risk of anthracycline-related heart damage for informational purposes only and does not constitute medical advice. Ask your oncology or cardio-oncology team how your health history and treatment plan affect you.

Get notified when new evidence is published on Cardiomyopathy due to anthracyclines.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.